Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database)

American Journal of Cardiology

Volumn 101, Issue 9, 2008, Pages 1242-1246

  Albert, Nancy M ^a   Birtcher, Kimberly K ^b   Cannon, Christopher P ^c   Goff Jr , David C ^d   Mulgund, Jyotsna ^e   Liang, Li ^e   Fonarow, Gregg C ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DRUG USE; FEMALE; HEALTH CARE QUALITY; HEART REHABILITATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; STROKE;

AGED; ANTILIPEMIC AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PRESCRIPTIONS, DRUG; REGISTRIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; UNITED STATES;

EID: 43049151742     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.12.020     Document Type: Article

References (14)

1. Cannon C.P., Battler A., Brindis R.G., Cox J.L., Ellis S.G., Every N.R., Flaherty J.T., Harrington R.A., Krumholz H.M., Simoons M.L., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on clinical data standards (Acute Coronary Syndromes Writing Committee. J Am Coll Cardiol 38 (2001) 2114-2130
2. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
3. Simpson E., Beck C., Richard H., Eisenberg M.J., and Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance and persistence. Am Heart J 145 (2003) 438-444
4. DeWilde S., Carey I.M., Bremmer S.A., Richards N., Hilton S.R., and Cook D.G. Evolution of statin prescribing 1994-2001: a case of ageism but not sexism?. Heart 89 (2003) 417-421
5. Walley T., Folino-Gallo P., Stephens P., and Van Ganese E. Trends in prescribing and utilizations of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 60 (2005) 543-551
6. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid-lowering statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
7. Eagle K.A., Montoye C.K., Riba A.L., DeFranco A.C., Parrish R., and Skorcz S. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction. J Am Coll Cardiol 46 (2005) 1242-1248
8. Fonarow G.C., Abraham W.T., Albert N.M., Gattis Stough W., Gheorghiade M., Greenberg B.H., O'Connor C.M., Pieper K., Lena Sun J., Yancy C.W., and Young J.B. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure. Results of the Optimized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart failure (OPTIMIZE-HF). Arch Intern Med 167 (2007) 1493-1502
9. Austin P.C., Mamdani M.M., Juurlink D.N., Alter D.A., and Tu J.V. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. Am Heart J 151 (2006) 969-975
10. Smith C.S., Cannon C.P., McCabe C.H., Murphy S.A., Bentley J., and Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Am Heart J 149 (2005) 444-450
11. Afilalo J., Majdan A.A., and Eisenberg M.J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 93 (2007) 914-921
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
13. Ray K.K., Bach R.G., Cannon C.P., Cairns R., Kirtane A.J., Wiviott S.D., McCabe C.H., Braunwald E., Gibson C.M., and PROVE IT-TIMI 22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J 27 (2006) 2310-2316
14. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al., PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360 (2002) 1623-1630